Here are the Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Impact of high blood glucose, continuous glucose monitoring diabetes, impact of social media on teenagers, continuous glucose monitoring pdf, how does glucose affect the body, impact of tariffs, impact of data centers on communities, impact of technology on education, impact of big beautiful bill, blood glucose continuous monitoring.
Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis
Aim: The real-world benefits of continuous glucose monitoring (CGM) in the broad type 2 diabetes (T2D) population are not well studied. Our study evaluated the impact of CGM use on health care resource utilization over 12 months in adults with T2D. Materials and
Methods: This retrospective cohort analysis used Optum's de-identified Market Clarity data of >79 million people to evaluate CGM use in people with T2D who were treated with non-insulin (NIT), basal insulin (BIT) and prandial insulin therapy (PIT). The primary outcomes were changes in all-cause hospitalizations, acute diabetes-related hospitalizations and acute diabetes-related emergency room visits during the 6- and 12-month post-index period following transition from blood glucose monitoring to CGM. A pre-specified subgroup analysis assessed glucose control and medication changes among people with T2D over 1 year.
Results: The analysis included 74 679 adults with T2D ( NIT; n = 25 269), (BIT; n = 16 264) and (PIT; n = 33 146). Significant reductions in all-cause hospitalizations, acute diabetes-related hospitalizations and acute diabetes-related emergency room visits were observed in the 6-month post-index period that were sustained during the 6–12 month post-index period (NIT, −10.1%, −31.0%, −30.7%; BIT, −13.9%, −47.6%, −28.2%; and PIT, −22.6%, −52.7%, −36.6%, respectively). A subgroup analysis of 6030 people showed mean glycated haemoglobin reductions at approximately 3 months, which were also sustained throughout the post-index period: NIT, −1.1 (0.05)%; BIT, −1.1 (0.06)%; and PIT, −0.9 (0.04)%, p < 0.0001. Conclusions: CGM use in real-life across different therapeutic regimens in adults with T2D was associated with reductions in health care resource utilization with improved glucose control over 1 year. © 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Authors : Garg S.K.; Hirsch I.B.; Repetto E.; Snell-Bergeon J.; Ulmer B.; Perkins C.; Bergenstal R.M.
Source : John Wiley and Sons Inc
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1111/dom.15866 |
| ISSN | 14628902 |
| Volume | 26 |
You can download the article here
If You have any problem, contact us here